Social media

Post-marketing pharmacovigilance plays a crucial role in maintaining patient safety once a product reaches the market. While automation can streamline certain tasks, its implementation must be carefully managed to avoid ...

Early clinical trial designs—especially first-in-human (FIH) studies—are increasingly tailored to the unique needs of specific therapeutic areas. In neurodegenerative diseases, there is a growing shift toward flexible an...

Early clinical trial designs—especially first-in-human (FIH) studies—are increasingly tailored to the unique needs of specific therapeutic areas. In neurodegenerative diseases, there is a growing shift toward flexible an...

ICON is proud to be recognised among the top global companies in the world for female employees. As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful refle...

ICON is proud to be recognised among the top global companies in the world for female employees. This recognition is based on a comprehensive survey of approximately 120,000 women across more than 36 countries, highlight...

By prioritising community engagement, enabling remote enrollment, and clearly communicating risks and benefits, researchers and sponsors can help create safer, more inclusive clinical trials for pregnant individuals. Exp...

Planning an Integrated Summary of Safety and Efficacy (ISS/ISE) submission can be demanding, especially when studies differ in format or terminology. This blog explains how early preparation and the right integration str...

Planning an Integrated Summary of Safety and Efficacy (ISS/ISE) submission can be demanding, especially when studies differ in format or terminology. This blog explains how early preparation and the right integration str...

Connect with ICON experts at #ObesityWeek, booth \#520 to learn about our proven success designing and executing early phase studies, supported by a robust database of overweight/obese volunteers and in-house clinical re...

Over the past five years, ICON has participated in over 840 oncology and haematologic malignancy, and 83 non-malignant haematology, clinical studies globally. Meet ICON experts at #ASH25, booth \#2161 to learn how our fl...

Discover how GMP manufacturing can improve trial outcomes, reduce risk, and support regulatory success. During this webinar we will discuss the differences between GMP and USP compounding, and feature expert-led case stu...

Discover how GMP manufacturing can improve trial outcomes, reduce risk, and support regulatory success. During this webinar we will discuss the differences between GMP and USP compounding, and feature expert-led case stu...